Shane Schaffer, Cingulate CEO
December 9, 2021 07:15 AM EST
Financing

Cin­gu­late prices a down­sized pub­lic of­fer­ing as IPO par­ty ap­pears to die down

Nicole DeFeudis

Editor

A few months af­ter fil­ing its S-1, Cin­gu­late fi­nal­ly joined the biotech IPO crowd yes­ter­day — but it wasn’t greet­ed with quite the same fan­fare …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ver­tex’s non-opi­oid pill dis­ap­points in mid-stage chron­ic pain study

David Ep­stein gets $140M for Ot­ti­mo's bi­func­tion­al take on hot PD-1xVEGF field

Roche’s Parkin­son’s drug flunks sec­ond mid-stage tri­al

No­var­tis turns to BioAge for new tar­gets based on longevi­ty and ex­er­cise

Sang­amo strikes an­oth­er brain-tar­get­ing AAV part­ner­ship, this time with Astel­las

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

A service from the Financial Times